Evidence map›Paper›PMID 40008357›Full record

ArticleClinical kidney journal2025

Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study.

Francisco Madrid-Gambin, María José Pérez-Sáez, Alex Gómez-Gómez, Noemí Haro, Dolores Redondo-Pachón, Vanessa Dávalos-Yerovi, Ester Marco, Marta Crespo, Oscar J Pozo, Julio Pascual and 1 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Frailty Prevalence and Characterization Among Kidney Transplant Candidates in Spain: A Multicenter Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francisco Madrid-GambinApplied Metabolomics Research Group, Hospital del Mar Research Institute, Barcelona, Spain.ORCID https://orcid.org/0000-0001-9333-0014
María José Pérez-SáezNephrology Department, Hospital del Mar, Barcelona, Spain.ORCID https://orcid.org/0000-0002-8601-2699
Alex Gómez-GómezApplied Metabolomics Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
Noemí HaroApplied Metabolomics Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
Dolores Redondo-PachónNephrology Department, Hospital del Mar, Barcelona, Spain.
Vanessa Dávalos-YeroviPhysical Medicine and Rehabilitation Department, Parc de Salut Mar (Hospital del Mar-Hospital de l'Esperança), Rehabilitation Research Group, Hospital del Mar Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ester MarcoPhysical Medicine and Rehabilitation Department, Parc de Salut Mar (Hospital del Mar-Hospital de l'Esperança), Rehabilitation Research Group, Hospital del Mar Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Marta CrespoNephrology Department, Hospital del Mar, Barcelona, Spain.
Oscar J PozoApplied Metabolomics Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
Julio PascualNephrology Department, Hospital del Mar, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4735-7838
FRAILMar Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sarcopenia and frailty are often overlooked in assessing kidney transplant (KT) candidates with chronic kidney disease (CKD), potentially leading to poor post-transplant outcomes. This study aimed to identify metabolites associated with frailty and sarcopenia in KT candidates from the FRAILMar study. Methods: Between June 2016 and June 2020, we evaluated frailty and sarcopenia in 173 KT candidates using the Physical Frailty Phenotype and EGWSOP-2 criteria, respectively. Seventy-five metabolic markers from targeted pathways, previously linked to CKD, sarcopenia or frailty, were measured in serum samples. These markers were analyzed using adjusted and weighted generalized linear models. Metabolomic data were integrated with multi-modal data, such as comorbidities, using a factor-based integration algorithm to identify metabolic phenotypes. Results: Increased metabolites related to energy metabolism and essential amino acids were associated with frailty, mainly Krebs cycle intermediates. Sarcopenic KT candidates showed lower levels of aromatic amino acids, and lower protein/muscle metabolism, energy metabolism and neurotransmission compared with non-sarcopenic patients. Unsupervised multi-modal integration revealed a high-risk metabolic phenotype characterized by the presence of sarcopenia, diabetes mellitus and low body mass index, with alterations in branched-chain amino acids and high activity of lactate dehydrogenase enzyme. Conclusions: Frailty and sarcopenia are common among KT candidates, and their metabolic status reveals notable disruptions in energy and amino acid metabolism. These findings highlight the value of a detailed metabolic assessment to more accurately evaluate patient health status prior to transplantation.

Indexed as

chronic kidney diseasefrailtymetabolomicssarcopeniatransplant

Identifiers

PMID40008357
PMCPMC11852263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.